K. Shitara Et Al. , "KEYNOTE-061: Phase 3 study of pembrolizumab vs paclitaxel for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer," ESMO 20th World Congress on Gastrointestinal Cancer , vol.29, Barcelona, Spain, 2018
Shitara, K. Et Al. 2018. KEYNOTE-061: Phase 3 study of pembrolizumab vs paclitaxel for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer. ESMO 20th World Congress on Gastrointestinal Cancer , (Barcelona, Spain).
Shitara, K., Ozguroglu, M., Bang, Y. J., Di Bartolomeo, M., Mandala, M., Ryu, M. H., ... Fornaro, L.(2018). KEYNOTE-061: Phase 3 study of pembrolizumab vs paclitaxel for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer . ESMO 20th World Congress on Gastrointestinal Cancer, Barcelona, Spain
Shitara, K. Et Al. "KEYNOTE-061: Phase 3 study of pembrolizumab vs paclitaxel for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer," ESMO 20th World Congress on Gastrointestinal Cancer, Barcelona, Spain, 2018
Shitara, K. Et Al. "KEYNOTE-061: Phase 3 study of pembrolizumab vs paclitaxel for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer." ESMO 20th World Congress on Gastrointestinal Cancer , Barcelona, Spain, 2018
Shitara, K. Et Al. (2018) . "KEYNOTE-061: Phase 3 study of pembrolizumab vs paclitaxel for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer." ESMO 20th World Congress on Gastrointestinal Cancer , Barcelona, Spain.
@conferencepaper{conferencepaper, author={K. Shitara Et Al. }, title={KEYNOTE-061: Phase 3 study of pembrolizumab vs paclitaxel for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer}, congress name={ESMO 20th World Congress on Gastrointestinal Cancer}, city={Barcelona}, country={Spain}, year={2018}}